Kevin Gorman | CEO & Director |
Jane Sorensen | Head, IR |
Matthew Abernethy | CFO |
Eiry Roberts | Chief Medical Officer |
Kyle Gano | Chief Business Development & Strategy Officer |
Eric Benevich | Chief Commercial Officer |
Brian Skorney | Robert W. Baird & Co. |
Paul Matteis | Stifel, Nicolaus & Company |
Biren Amin | Jefferies |
Philip Nadeau | Cowen and Company |
Anupam Rama | JPMorgan Chase & Co. |
Jay Olson | Oppenheimer |
Charles Duncan | Cantor Fitzgerald & Co. |
David Amsellem | Piper Jaffray Companies |
Jeff Hung | Morgan Stanley |
Marc Goodman | SVB Leerink |
Evan Seigerman | Crédit Suisse |
Tazeen Ahmad | Bank of America Merrill Lynch |
Hello, and thank you for joining the Neurocrine Biosciences Reports Second Quarter 2019 Results Call. [Operator Instructions]. It is now my pleasure to turn today's conference over to Kevin Gorman, CEO. Please go ahead.
Thank you very much, and thank you, everyone, for taking the time to join us on our Q2 earnings call.